Emergent BioSolutions reported a $191.3 million non-cash impairment charge on its NARCAN asset group, resulting in a GAAP net loss of $180.2 million for the quarter ended June 30, 2026. The company also lowered its full-year revenue guidance by about 10.8%, citing increased competition affecting its outlook and asset value. Following this announcement, Emergent's stock price plunged nearly 30%. Pomerantz LLP has launched an investigation into whether Emergent and its executives engaged in securities fraud or other unlawful practices, potentially leading to a class action lawsuit.
Emergent BioSolutions is the subject of an investor alert regarding a legal investigation. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: out of 91 priced US health stocks, 59 rose and 31 fell. Notable movers include RXRX at USD 3.37 with a 5.64% increase and 100% buy order activity, ILMN at USD 241.64 with a 5.55% rise and 97% sell order activity, and DNA at USD 7.44 with a 5.38% gain.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
